共 36 条
[1]
Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. Technology Appraisal Guidance No. 19, (2001)
[2]
Brazier J., Deverill M., Green C., Harper R., Booth A., A review of the use of health status measures in economic evaluation, Health Technol Assess, 3, 9, (1999)
[3]
Zimmerman S.I., Magaziner J., Methodological issues in measuring the functional status of cognitively impaired nursing home residents: The use of proxies and performance based measures, Alzheimer Disease Assoc Disorders, 8, 1 SUPPL., (1994)
[4]
Selai C., Trimble M.R., Assessing quality of life in dementia, Aging Mental Health, 3, 2, pp. 101-111, (1999)
[5]
Magaziner J., Use of proxies to measure health and functional outcomes in effectiveness research in persons with Alzheimer disease and related disorders, Alzheimer Dis Associ Disorders, 6 SUPPL., pp. 168-174, (1997)
[6]
Rabin R., De Charro F., EQ-5D: A measure of health status from the EuroQol Group, Ann Med, 33, pp. 337-343, (2001)
[7]
Coucill W., Bryan S., Bentham P., Buckley A., Laight A., EQ-5D as a measure of health-related quality of life in patients with cognitive impairment: An investigation of inter-rater reliability, 16th Plenary Meeting of the EuroQol Group, pp. 169-188, (1999)
[8]
Coucill W., Bryan S., Bentham P., Buckley A., Laight A., EQ-5D in dementia: An investigation of inter-rater agreement, Med Care, 39, 8, pp. 760-771, (2001)
[9]
Devellis R.F., Scale Development - Theory and Applications, (1991)
[10]
Bucks R.S., Ashworth D., Wilcock G.K., Siegfried K., Assessment of daily living in dementia: Development of the Bristol Activities of Daily Living Scale, Age Ageing, 25, pp. 113-120, (1996)